000075798 001__ 75798
000075798 005__ 20191122145053.0
000075798 0247_ $$2doi$$a10.2147/PPA.S164819
000075798 0248_ $$2sideral$$a108466
000075798 037__ $$aART-2018-108466
000075798 041__ $$aeng
000075798 100__ $$aMenditto, E.
000075798 245__ $$aAdherence to chronic medication in older populations: application of a common protocol among three European cohorts
000075798 260__ $$c2018
000075798 5060_ $$aAccess copy available to the general public$$fUnrestricted
000075798 5203_ $$aPurpose:
The purpose of this study was to evaluate and compare medication adherence to chronic therapies in older populations across different regions in Europe.
Methods:
This explorative study applied a harmonized method of data extraction and analysis from pharmacy claims databases of three European countries to compare medication adherence at a cross-country level. Data were obtained for the period between January 1, 2010, and December 31, 2011. Patients (aged >= 65 years) who newly initiated to oral antidiabetics, antihyperlipidemics, or antiosteoporotics were identified and followed for over a 12-month period. Main outcome measures were medication adherence (medication possession ratio, [MPR]; implementation) and persistence on index treatment. All country-specific data sets were prepared by employing a common data input model. Outcome measures were calculated for each country and pooled using random effect models.
Results:
In total, 39, 186 new users were analyzed. In pooled data from the three countries, suboptimal implementation (MPR <80%) was 52.45% (95% CI: 33.43-70.79) for antihyperlipidemics, 61.35% (95% CI: 52.83-69.22) for antiosteoporotics, and 30.33% (95% CI: 25.53-35.60) for oral antidiabetics. Similarly, rates of non-persistence (discontinuation) were 55.63% (95% CI: 35.24-74.29) for antihyperlipidemics, 60.24% (95% CI: 45.35-73.46) for antiosteoporotics, and 46.80% (95% CI: 36.40-57.4) for oral antidiabetics.
Conclusion:
Medication adherence was suboptimal with >50% of older people non-adherent to antihyperlipidemics and antiosteoporotics in the three European cohorts. However, the degree of variability in adherence rates among the three countries was high. A harmonized method of data extraction and analysis across health-related database in Europe is useful to compare medication-taking behavior at a cross-country level.
000075798 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000075798 590__ $$a2.097$$b2018
000075798 591__ $$aMEDICINE, GENERAL & INTERNAL$$b59 / 159 = 0.371$$c2018$$dQ2$$eT2
000075798 592__ $$a0.757$$b2018
000075798 593__ $$aHealth Policy$$c2018$$dQ1
000075798 593__ $$aSocial Sciences (miscellaneous)$$c2018$$dQ1
000075798 593__ $$aPharmacology, Toxicology and Pharmaceutics (miscellaneous)$$c2018$$dQ1
000075798 593__ $$aMedicine (miscellaneous)$$c2018$$dQ1
000075798 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000075798 700__ $$aCahir, C.
000075798 700__ $$aAza-Pascual-Salcedo, M.
000075798 700__ $$aBruzzese, D.
000075798 700__ $$aPoblador-Plou, B.
000075798 700__ $$0(orcid)0000-0002-7194-8275$$aMalo, S.$$uUniversidad de Zaragoza
000075798 700__ $$aCosta, E.
000075798 700__ $$0(orcid)0000-0003-2580-2002$$aGonzalez-Rubio, F.
000075798 700__ $$aGimeno-Miguel, A.
000075798 700__ $$aOrlando, V.
000075798 700__ $$aKardas, P.
000075798 700__ $$aPrados-Torres, A.
000075798 7102_ $$11008$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Medic.Prevent.Salud Públ.
000075798 773__ $$g12 (2018), 1975-1987$$pPATIENT PREFERENCE AND ADHERENCE$$tPATIENT PREFERENCE AND ADHERENCE$$x1177-889X
000075798 8564_ $$s511774$$uhttps://zaguan.unizar.es/record/75798/files/texto_completo.pdf$$yVersión publicada
000075798 8564_ $$s18419$$uhttps://zaguan.unizar.es/record/75798/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000075798 909CO $$ooai:zaguan.unizar.es:75798$$particulos$$pdriver
000075798 951__ $$a2019-11-22-14:44:07
000075798 980__ $$aARTICLE